Seattle Genetics Archives -

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after

MHRA approves Seagen’s oral HER2 drug Tukysa

https://pharmaphorum.com/news/mhra-approves-seagens-oral-her2-drug-tukysa/

News/ News/ Oncology

Merck & Co signs multi-billion cancer drug development deal with Seattle Genetics

Richard Staines breast cancer, cancer, Merck & Co, Seattle Genetics 0 Comment

Merck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion

Merck & Co signs multi-billion cancer drug development deal with Seattle Genetics

https://pharmaphorum.com/news/merck-co-signs/

News/ News/ Oncology

Seattle Genetics snags early approval for advanced breast cancer drug

Richard Staines breast cancer, fda, Seattle Genetics, Tukysa 0 Comment

The FDA has approved Seattle Genetics’ breast cancer drug Tukysa (tucatinib) four months early, including in certain patients

Seattle Genetics snags early approval for advanced breast cancer drug

https://pharmaphorum.com/news/fda-approves-seattle-genetics-advanced-breast-cancer-drug/

News/ News/ Oncology/ Top stories

FDA sets August action date for Seattle’s oral HER2 drug tucatinib

Phil Taylor breast cancer, her2, Oncology, Priority Review, Seattle Genetics, tucatinib 0 Comment

Seattle Genetics is a few months away from having its third drug product on the market, after the

FDA sets August action date for Seattle’s oral HER2 drug tucatinib

https://pharmaphorum.com/news/fda-sets-august-action-date-for-seattles-oral-her2-drug-tucatinib/

News/ News/ Oncology

Seattle Genetics says data backs Padcev combo for first-line bladder cancer

Phil Taylor Astellas, bladder cancer, Oncology, Padcev, Seattle Genetics 0 Comment

Seattle Genetics and Astellas’ new drug for relapsed bladder cancer – Padcev – could move up the treatment

Seattle Genetics says data backs Padcev combo for first-line bladder cancer

https://pharmaphorum.com/news/seattle-genetics-says-data-backs-padcev-combo-for-first-line-bladder-cancer/

News/ News/ Oncology/ Top stories

FDA backs Astellas/Seattle Genetics bladder cancer drug

Richard Staines Astellas, bladder cancer, cancer, Padcev, Seattle Genetics 0 Comment

The FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the

FDA backs Astellas/Seattle Genetics bladder cancer drug

https://pharmaphorum.com/news/fda-backs-astellas-seattle-genetics-bladder-cancer-drug/

News/ News/ Oncology

AZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced disease

Richard Staines AstraZeneca, breast cancer, Daiichi Sankyo, Seattle Genetics 0 Comment

AstraZeneca had to ask shareholders for $3.5 billion in extra cash to finance an R&D tie-up with Daiichi

AZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced disease

https://pharmaphorum.com/news/az-daiichi-sankyos-breast-cancer-drug-delays-progression-in-advanced-disease/

News/ News/ Oncology/ Top stories

Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates

Richard Staines AstraZeneca, breast cancer, Daiichi Sankyo, Seattle Genetics 0 Comment

Big-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and

Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates

https://pharmaphorum.com/news/daiichi-sankyo-takes-seattle-genetics-to-court-as-battle-over-breast-cancer-drug-escalates/

News/ News/ Oncology

Seattle Genetics plans to file breast cancer drug tucatinib

Richard Staines breast cancer, cancer, Roche, Seattle Genetics 0 Comment

Seattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in

Seattle Genetics plans to file breast cancer drug tucatinib

https://pharmaphorum.com/news/seattle-genetics-plans-to-file-breast-cancer-drug/

Trending

Seattle Genetics

Login